Accessibility Menu
Cell Source logo

Cell Source(OTC) CLCS

Current Price$0.80
Market Cap$55.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-48%
5 Year-58%
1 Year+105%
1 Month+2%
Cell Source last closing stock price
MetricPriceDate
Last closeUSD 0.802026-07-21
Cell Source stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.13%USD 0.772026-07-14
1 month+2.28%USD 0.782026-06-18
3 month-4.76%USD 0.842026-04-22
Year to date+60%USD 0.502025-12-31
1 year+105.13%USD 0.392025-07-21
3 year+37,995.24%USD 0.002023-07-13
5 year-57.89%USD 1.902021-07-22
Since inception-48.39%USD 1.552014-07-01

Cell Source Financials at a Glance

Market Cap

$55.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$4.77M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

135.66 (High)

Price

$0.80

Volume

504

Open

$0.69

Previous Close

$0.80

Daily Range

$0.69 - $0.80

52-Week Range

$0.30 - $2.25

Estimated Earnings Date

Nov 12, 2025

CLCS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cell Source

Cell Source develops cell therapies to help patients accept transplants. Its technology aims to reduce immune rejection in blood cancers and organ transplants. The company’s work targets people needing stem cell or organ transplants.

Products and Services

  • Veto Cell Therapy: Experimental treatment to help the body accept donor cells or organs; no revenue yet.
  • VETO CAR-T HSCT: Cell therapy in development for blood cancer patients needing stem cell transplants; pre-commercial.
  • Organ Transplant Tolerance: Therapy to reduce rejection in kidney and liver transplants; still in trials.
  • Off-the-shelf VETO CAR-T: Planned therapy for blood cancers and solid tumors; not yet available.
  • Non-malignant Disease Therapy: Early-stage research for conditions like sickle cell anemia and type 1 diabetes.

Growth and Expansion

  • Formed research partnership with MD Anderson Cancer Center in 2018, expanding clinical trials.
  • Secured exclusive technology license from Yeda Research and Development since 2012, with multiple amendments.
  • Expanded clinical trial at MD Anderson in 2023 to include more patients and indications.
  • Collaborated with the inventor of CAR-T therapy for preclinical proof-of-concept in 2023.

What Makes Cell Source Special

Cell Source holds exclusive rights to a large patent portfolio for its Veto Cell technology. The company partners with leading research centers to advance its therapies. Its focus is on making transplants safer and more accessible for patients with few options.

Five Things You Need to Know

  • No revenue in 2024, 2023, or 2022; all products are pre-commercial.
  • Net loss was $4.5 million in 2024, improved 15% from 2023.
  • Research and development expense rose 20% to $1.9 million in 2024.
  • Cash balance was $74,631 at year-end 2024; working capital deficit was $18.5 million.
  • Company relies on raising new capital and faces ongoing financial risk.

Bottom Line

Cell Source is an early-stage biotech focused on immune tolerance for transplants. Its future depends on clinical progress and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Itamar Shimrat, MBA

Website

www.cell-source.com

Headquarters

New York City, NY 10019, US

CLCS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

22.48%

Return on Capital

N/A

Return on Assets

-999.35%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$55.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

68.86M

Volume

504

Avg. Volume

2.50K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$3.85M

EBITDA

-$3.48M

Operating Cash Flow

-$2.68M

Capital Expenditure

$0.00

Free Cash Flow

-$2.68M

Cash & ST Invst.

$74.63K

Total Debt

$10.07M

Cell Source Performance Analysis

Cell Source annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Cell Source sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-31N/A
Q22024-06-30N/A
Q32024-09-30N/A
Q42024-12-31N/A
Cell Source annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.18-6.7%
20232023-12-31USD -0.17-4.6%
20242024-12-31USD -0.14-18.9%
20252025-12-31USD -0.10-26.8%
Cell Source sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-31-12.2%
Q22024-06-30-12.9%
Q32024-09-306.5%
Q42024-12-3149.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$55.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$55.09M

N/A

Employees

1

N/A

Net Income

-$589.71K

+43.8%

EBITDA

-$375.86K

+62.3%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$74.63K

+236.1%

Total Debt

$10.07M

+8.8%

Accounts Receivable

$50.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$10.07M

+8.8%

Return on Assets

-9.99%

N/A

Return on Invested Capital

12.13%

N/A

Free Cash Flow

-$748.33K

-3.6%

Operating Cash Flow

-$748.33K

-3.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TELIFTelescope Innovations Corp.
$0.31+1.79%
ZHCLFZenith Capital Corp.
$0.05+0.00%
SRBCFSirona Biochem Corp.
$0.01+0.00%
HSITFHadasit Bio-Holdings Ltd
$0.12+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
INTCIntel
$102.62-0.03%
AALAmerican Airlines Group
$14.79-0.03%

Questions About CLCS

What is the current price of Cell Source?

Cell Source is trading at $0.80 per share.

What is the 52-week range for Cell Source?

Over the past 52 weeks, Cell Source has traded between $0.30 and $2.25.

How much debt does Cell Source have?

As of the most recent reporting period, Cell Source reported total debt of $10.82M.

How much cash does Cell Source have on hand?

Cell Source reported $1.24K in cash and cash equivalents in its most recent financial results.

What is Cell Source’s dividend yield?

Cell Source does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services